Ignite Creation Date:
2024-05-06 @ 5:01 PM
Last Modification Date:
2024-10-26 @ 2:20 PM
Study NCT ID:
NCT05169567
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-26
First Post:
2021-12-22
Brief Title:
Abemaciclib LY2835219 Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-03-11
Start Date Type:
ACTUAL
Primary Completion Date:
2024-02-08
Primary Completion Date Type:
ACTUAL
Completion Date:
2026-02-16
Completion Date Type:
ESTIMATED
First Submit Date:
2021-12-22
First Submit QC Date:
December 22 2021
Study First Post Date:
2021-12-27
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-09-25
Last Update Post Date:
2024-06-26
Last Update Post Date Type:
ACTUAL